Recent News

• 12.03.2025 - Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models
• 11.12.2025 - Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.04.2025 - Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
• 10.15.2025 - Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
• 10.01.2025 - Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Recent Filings

• 11.25.2025 - 8-K Current report
• 11.17.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 11.17.2025 - 3 Initial statement of beneficial ownership of securities
• 11.14.2025 - 8-K Current report
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.10.2025 - D Notice of Exempt Offering of Securities
• 10.31.2025 - 8-K Current report
• 10.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.30.2025 - 4 Statement of changes in beneficial ownership of securities